TY - JOUR AU - Oza, AM AU - Lisyanskaya, A AU - Fedenko, A AU - de Melo, AC AU - Shparyk, Y AU - Rakhmatulina, I AU - Bondarenko, I AU - Colombo, N AU - Svintsitskiy, V AU - Biela, L AU - Nechaeva, M AU - Lorusso, D AU - Scambia, G AU - Cibula, D AU - Póka, Róbert AU - Oaknin, A AU - Safra, T AU - Mackowiak-Matejczyk, B AU - Ma, L AU - Thomas, D AU - Lin, KK AU - McLachlan, K AU - Goble, S AU - Kristeleit, R TI - Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 SP - 249 EP - 264 PG - 16 SN - 1470-2045 DO - 10.1016/S1470-2045(24)00674-0 UR - https://m2.mtmt.hu/api/publication/35737654 ID - 35737654 LA - English DB - MTMT ER - TY - JOUR AU - Mateos, M.-V. AU - San-Miguel, J. AU - Cavo, M. AU - Suzuki, K. AU - Jakubowiak, A. AU - Knop, S. AU - Doyen, C. AU - Lucio, P. AU - Nagy, Zsolt AU - Pour, L. AU - Grosicki, S. AU - Crepaldi, A. AU - Liberati, A.M. AU - Campbell, P. AU - Yoon, S.-S. AU - Iosava, G. AU - Fujisaki, T. AU - Garg, M. AU - Ngo, M. AU - Katz, E.G. AU - Krevvata, M. AU - Bolyard, K. AU - Carson, R. AU - Borgsten, F. AU - Dimopoulos, M.A. TI - Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 5 SP - 596 EP - 608 PG - 13 SN - 1470-2045 DO - 10.1016/S1470-2045(25)00018-X UR - https://m2.mtmt.hu/api/publication/36105787 ID - 36105787 N1 - University Hospital of Salamanca/IBSAL/Cancer Research Center–IBMCC (USAL-CSIC), Salamanca, Spain Cancer Center Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain IRCCS Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan University of Chicago Medical Center, Chicago, IL, United States Department of Hematology, Oncology and Stem Cell Transplantation, Nuremberg General Hospital, Paracelsus Medical School, Nuremberg, Germany Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium Champalimaud Centre for the Unknown, Lisbon, Portugal Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary University Hospital and Masaryk University Brno, Brno, Czech Republic Department of Hematology and Cancer Prevention in Chorzów, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, Katowice, Poland Clinica de Tratamento E, Cuiaba, Brazil Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria, Terni, Italy Andrew Love Cancer Centre, University Hospital Geelong, Geelong, VIC, Australia Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea Medinvest-Institute of Hematology, Tbilisi, Georgia Matsuyama Red Cross Hospital, Matsuyama, Japan Leicester Royal Infirmary – Haematology, Leicester, United Kingdom Janssen Research & Development, LLC, Titusville, NJ, United States Janssen Research & Development, LLC, Raritan, NJ, United States Janssen Research & Development, LLC, Spring House, PA, United States Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece Export Date: 26 June 2025; Cited By: 1; Correspondence Address: M.-V. Mateos; University Hospital of Salamanca/IBSAL/Cancer Research Center–IBMCC (USAL-CSIC), Salamanca, 37007, Spain; email: mvmateos@usal.es; CODEN: LOANB LA - English DB - MTMT ER - TY - JOUR AU - Gamper, Eva Maria AU - King, Madeleine T AU - Shaw, Jim W AU - Schiel, Anja AU - Kaló, Zoltán AU - van, der Weijst Lotte AU - Cella, David AU - Reijneveld, Jaap C AU - Pe, Madeline TI - Shifting perspectives: a reflection on cancer-specific quality-of-life metrics in cancer care economics JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 5 SP - 545 EP - 547 PG - 3 SN - 1470-2045 DO - 10.1016/S1470-2045(25)00066-X UR - https://m2.mtmt.hu/api/publication/36120084 ID - 36120084 LA - English DB - MTMT ER - TY - JOUR AU - Gupta, Vikas AU - Satlin, Michael J. AU - Yu, Kalvin C. AU - Martei, Yehoda AU - Sung, Lillian AU - Westblade, Lars F. AU - Howard, Scott AU - Ai, ChinEn AU - Flayhart, Diane C. TI - Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 5 SP - 620 EP - 628 PG - 9 SN - 1470-2045 DO - 10.1016/S1470-2045(25)00128-7 UR - https://m2.mtmt.hu/api/publication/36183494 ID - 36183494 N1 - Funding Agency and Grant Number: AMR Action Fund Funding text: Acknowledgments This work was supported by a grant from the AMR Action Fund. We thank Nicole Cooper (Voorhees, NJ, USA) for providing medical writing assistance for this manuscript. AB - Background Infections are the second leading cause of death in patients with cancer and are often caused by resistant bacteria. However, the frequency of antimicrobial resistance (AMR) in outpatients with cancer is not well understood. We aimed to compare the frequency of AMR bacterial pathogens in outpatients with and without cancer. Methods This retrospective cohort study evaluated antimicrobial susceptibility of bacteria isolated from adults (aged >= 18 years) with and without cancer seeking care in 198 outpatient health-care settings in the USA. Data were collected using the BD Insights Research Database. Patients who were not prescribed cancer medications or not admitted to an inpatient cancer unit in the predefined period were categorised as patients without cancer. Patients were included in the cancer cohort if they received medication solely or sometimes indicated for cancer. Data on gender and race or ethnicity were not collected. Non-duplicate and non-contaminant pathogens collected from various samples (ie, blood, intra-abdominal, respiratory, urine, skin or wound, and other) in outpatients were used to assess the coprimary outcomes: overall and source-specific proportions of non-susceptible pathogen isolates with corresponding AMR odds ratios (ORs); and rates of AMR pathogens per 1000 isolates with corresponding AMR incidence rate ratio (IRR) in patients with and without cancer. Findings Data were collected between April 1, 2018, and Dec 31, 2022. 53 006 (3 center dot 2%) of 1 655 594 pathogens identified were from 27 421 patients with cancer and 1 602 588 (96 center dot 8%) were from 928 128 patients without cancer. For Pseudomonas aeruginosa, carbapenem non-susceptibility was higher in pathogen isolates from patients with cancer (816 [14 center dot 4%] of 5683) than patients without cancer (10 709 [11 center dot 3%] 94 419; OR 1 center dot 22 [95% CI 1 center dot 13-1 center dot 32]). For Enterobacterales, fluoroquinolone non-susceptibility was higher in pathogen isolates from patients with cancer (8662 [28 center dot 0%] of 30 867) than patients without cancer (238 479 [21 center dot 8%] of 1 095 996; OR 1 center dot 44 [1 center dot 40-1 center dot 47]), as was carbapenem non-susceptibility (472 [1 center dot 5%] of 30 867 vs 9165 [0 center dot 8%] of 1 095 996; OR 1 center dot 89 [1 center dot 72-2 center dot 07]), multidrug-resistant pathogens (2672 [8 center dot 7%] of 30 867 vs 48 962 [4 center dot 5%] of 1 095 996; OR 2 center dot 03 [1 center dot 95-2 center dot 11]), and extended-spectrum beta-lactamase producers (4343 [16 center dot 5%] of 26 327 vs 93 977 [9 center dot 4%] of 996 853; OR 1 center dot 96 [1 center dot 90-2 center dot 03]). For Staphylococcus aureus, meticillin resistance was higher in pathogen isolates from patients with cancer (4747 [53 center dot 0%] of 8959) than patients without cancer (129 291 [48 center dot 3%] of 267 520; OR 1 center dot 20 [1 center dot 15-1 center dot 25]). For Enterococcus spp, vancomycin resistance was higher in pathogen isolates from patients with cancer (1329 [18 center dot 6%] of 7145) than patients without cancer (12 333 [9 center dot 1%] of 135 772]; ORR 2 center dot 20 [2 center dot 06-2 center dot 34). The rates and corresponding IRRs of AMR pathogens per 1000 isolates was also higher in patients with cancer compared with patients without cancer, particularly for carbapenem non-susceptible P aeruginosa (IRR 2 center dot 06 [1 center dot 91-2 center dot 21]) and vancomycin-resistant enterococci (IRR 3 center dot 06 [2 center dot 89-3 center dot 24]). For all comparisons, p<0 center dot 0001. Interpretation AMR proportions and IRRs for most key pathogens were up to three-times higher in isolates from outpatients with cancer than those without cancer, highlighting the need for enhanced surveillance, infection prevention, and timely diagnostic stewardship to improve antibiotic prescribing in this population. Copyright (c) 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. LA - English DB - MTMT ER - TY - JOUR AU - Levy, A. AU - Massard, C. AU - Michiels, S. AU - Deutsch, E. TI - Innovative, early-phase clinical trials of drug–radiotherapy combinations JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 4 SP - e190 EP - e202 SN - 1470-2045 DO - 10.1016/S1470-2045(24)00664-8 UR - https://m2.mtmt.hu/api/publication/36103011 ID - 36103011 N1 - Department of Radiation Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France Gustave Roussy, Inserm U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Université Paris Saclay, Villejuif, France Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicêtre, France Drug Development Department (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France Office of Biostatistics and Epidemiology Department, Gustave Roussy, Université Paris Saclay, Villejuif, France Oncostat U1018, Inserm, Labeled Ligue Contre le Cancer, Université Paris Saclay, Villejuif, France Export Date: 23 April 2025; Cited By: 0; Correspondence Address: A. Levy; Department of Radiation Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, 94850, France; email: antonin.levy@gustaveroussy.fr; CODEN: LOANB AB - Over the past few decades, breakthroughs in cancer biology at the molecular level have revolutionised cancer treatment. Enhanced precision in radiotherapy has not only reduced patient side-effects, but also enabled the delivery of high-dose stereotactic extracranial irradiation with unprecedented accuracy. Simultaneously, the number of medical therapies available for clinical care continues to grow. Despite the progress made with combined chemoradiotherapy, only a few drug–radiotherapy combinations have received clinical approval, leaving a vast landscape of untapped opportunities for basic, translational, and clinical research, particularly in early-phase drug–radiotherapy trials. New and promising pharmaceutical therapies, paired with advanced radiotherapy technologies, are now being tested in innovative clinical trial designs. Moreover, the integration of biological and imaging markers—both tumour-specific and peripheral—holds the potential to personalise drug–radiotherapy combinations, thereby enhancing the therapeutic index for specific patient populations. In this Review, we highlight the latest developments and future directions for early-phase clinical trials that combine precision drug–radiotherapy strategies in adult patients, with the aims of improving outcomes and expanding treatment options. © 2025 Elsevier Ltd LA - English DB - MTMT ER - TY - JOUR AU - Espinoza, P. AU - Rice, H.E. AU - Wise, P.H. AU - Bhakta, N. AU - Mueller, A. AU - Yakimkova, T. AU - Force, L.M. AU - Smith, E.R. AU - Agulnik, A. TI - The impact of armed conflict on global patterns of childhood cancer JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 4 SP - 421 EP - 424 PG - 4 SN - 1470-2045 DO - 10.1016/S1470-2045(24)00559-X UR - https://m2.mtmt.hu/api/publication/36111216 ID - 36111216 N1 - Department of Surgery, Duke University School of Medicine, Durham, 27705, NC, United States Department of Emergency Medicine, Duke University School of Medicine, Durham, 27705, NC, United States Duke Global Health Institute, Center for Global Surgery and Health Equity, Duke University School of Medicine, Durham, NC, United States Department of Pediatrics, Stanford University, Stanford, CA, United States Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, United States Department of Pediatric Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany Department of Health Metrics Sciences and Department of Pediatrics, Division of Hematology/Oncology, University of Washington, Seattle, WA, United States Export Date: 28 April 2025; Cited By: 0; CODEN: LOANB LA - English DB - MTMT ER - TY - JOUR AU - Dee, E.C. AU - Laversanne, M. AU - Bhoo-Pathy, N. AU - Ho, F.D.V. AU - Feliciano, E.J.G. AU - Eala, M.A.B. AU - Ting, F.I.L. AU - Ginsburg, O. AU - Moraes, F.Y. AU - Gyawali, B. AU - Gomez, S.L. AU - Ng, K. AU - Wu, J.F. AU - Jain, U. AU - Jain, B. AU - Columbres, R.C. AU - Matsuda, T. AU - Sangrajrang, S. AU - Sinuraya, E.S. AU - Bui, T.D. AU - Wei, W. AU - Won, Y.-J. AU - Foo, L.L. AU - Ling, M.C.A. AU - Mery, L. AU - Soerjomataram, I. AU - Bray, F. TI - Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 4 SP - 516 EP - 528 PG - 13 SN - 1470-2045 DO - 10.1016/S1470-2045(25)00017-8 UR - https://m2.mtmt.hu/api/publication/36111349 ID - 36111349 N1 - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France Centre for Epidemiology and Evidence-Based Practice, Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia College of Medicine, University of the Philippines, Manila, Philippines Ateneo School of Medicine and Public Health, Ateneo de Manila University, Pasig City, Philippines Department of Medicine, NYC Health+Hospitals/Elmhurst, Icahn School of Medicine at Mount Sinai, Queens, New York, NY, United States Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States Division of Medical Oncology, Department of Internal Medicine, Corazon Locsin Montelibano Memorial Regional Hospital, Bacolod, Philippines Department of Clinical Sciences, College of Medicine, University of St La Salle, Bacolod, Philippines Centre for Global Health, National Cancer Institute, Rockville, MD, United States Department of Oncology, Kingston General Hospital, Queen's University, Kingston, ON, Canada Department of Radiology and Oncology, University of São Paulo Medical School, São Paulo, Brazil Division of Cancer Care and Epidemiology, Queen's University, Kingston, ON, Canada Departments of Oncology and Public Health Sciences, Queen's University, Kingston, ON, Canada Department of Epidemiology and Biostatistics and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States Department of Medical Oncology, Barts Cancer Centre, London, United Kingdom Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States University of Pittsburgh School of Medicine, Pittsburgh, PA, United States Department of Health Policy, Stanford University School of Medicine, Stanford, CA, United States Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States College of Osteopathic Medicine, William Carey University, Hattiesburg, MS, United States Center for Cancer Registries, National Cancer Center Institute for Cancer Control, Tokyo, Japan National Cancer Institute, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand Department of National Quality Control for Cancer Burden and Networking, Dharmais National Cancer Center, Jakarta, Indonesia Ho Chi Minh Cancer Registry, Ho Chi Minh City Oncological Hospital, Ho Chi Minh City, Viet Nam National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China Division of Health Administration, College of Software Digital Healthcare Convergence, Yonsei University, Wonju, South Korea Health Promotion Board, Singapore Saw Swee Hock School of Public Health, National University of Singapore, Singapore Export Date: 28 April 2025; Cited By: 1; Correspondence Address: F. Bray; Cancer Surveillance Branch, International Agency for Research on Cancer, 69366 Lyon Cedex 07, France; email: brayf@iarc.who.int; CODEN: LOANB LA - English DB - MTMT ER - TY - JOUR AU - Tannock, Ian F. AU - de Vries, Elisabeth G. E. AU - Fojo, Antonio AU - Buyse, Marc AU - Moja, Lorenzo TI - Dose optimisation to improve access to effective cancer medicines JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 3 SP - e171 EP - e180 PG - 10 SN - 1470-2045 DO - 10.1016/S1470-2045(24)00648-X UR - https://m2.mtmt.hu/api/publication/35980388 ID - 35980388 N1 - Export Date: 22 April 2025; Cited By: 0; Correspondence Address: L. Moja; Health Products Policy and Standards, WHO, Geneva, 1211, Switzerland; email: mojal@who.int; CODEN: LOANB LA - English DB - MTMT ER - TY - JOUR AU - Morris, Zachary S. AU - Demaria, Sandra AU - Monjazeb, Arta M. AU - Formenti, Silvia C. AU - Weichselbaum, Ralph R. AU - Welsh, James AU - Enderling, Heiko AU - Schoenfeld, Jonathan AU - Brody, Joshua AU - Mcgee, Heather M. AU - Mondini, Michele AU - Kent, Michael S. AU - Young, Kristina H. AU - Galluzzi, Lorenzo AU - Karam, Sana AU - Theelen, Willemijn S. M. E. AU - Chang, Joe Y. AU - Huynh, Mai Anh AU - Daib, Adi AU - Pitroda, Sean AU - Chung, Caroline AU - Serre, Raphael AU - Grassberger, Clemens AU - Deng, Jie AU - Sodji, Quaovi H. AU - Nguyen, Anthony AU - Patel, Ravi B. AU - Krebs, Simone AU - Kalbasi, Anusha AU - Kerr, Caroline AU - Vanpouille-Box, Claire AU - Vick, Logan AU - Aguilera, Todd A. AU - Ong, Irene M. AU - Herrera, Fernanda AU - Menon, Hari AU - Smart, Deedee AU - Ahmed, Jalal AU - Gartrell, Robyn AU - Roland, Christina L. AU - Fekrmandi, Fatemeh AU - Chakraborty, Binita AU - Bent, Eric H. AU - Berg, Tracy J. AU - Hutson, Alan AU - Khleif, Samir AU - Sikora, Andrew G. AU - Fong, Lawrence TI - Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 3 SP - e152 EP - e170 PG - 19 SN - 1470-2045 UR - https://m2.mtmt.hu/api/publication/36009250 ID - 36009250 LA - English DB - MTMT ER - TY - JOUR AU - Zdenkowski, Nicholas AU - Kuper-Hommel, Marion J. J. AU - Niman, Samuel M. AU - Francis, Prudence A. AU - Baron-Hay, Sally AU - Fox, William AU - Menzies, Alexander M. AU - Angus, Rebecca AU - Punie, Kevin AU - Zardawi, Sarah AU - Regan, Meredith M. AU - Loi, Sherene TI - Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/ IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial JF - LANCET ONCOLOGY J2 - LANCET ONCOL VL - 26 PY - 2025 IS - 3 SP - 367 EP - 377 PG - 11 SN - 1470-2045 UR - https://m2.mtmt.hu/api/publication/36010395 ID - 36010395 LA - English DB - MTMT ER -